Chemed Corporation (CHE) Balance Sheet

The D/E ratio more than tripled from 0.12 to 0.40 over the period, indicating a deliberate increase in financial leverage. This trend appears to coincide with aggressive share repurchases, as cash reserves were drawn down to fund buybacks. Investors should monitor whether this leverage is temporary or signals a structural shift in capital allocation philosophy.

The increase in debt appears strategic, likely to fund buybacks, but it introduces refinancing risk and interest expense that could pressure margins. While the absolute debt level remains modest relative to equity, the rapid pace of accumulation warrants scrutiny. If cash generation falters, the company may face tighter liquidity, though current debt levels are still manageable.

The jump in goodwill from $591.5M in 2024Q1 suggests acquisition activity, possibly in the Roto-Rooter segment. The sharp decline in PPE net is unusual and may indicate a reclassification or impairment, though no impairment is disclosed. The asset mix implies a shift toward service-based operations with lower capital intensity, but the concentration in goodwill raises impairment risk if segment performance deteriorates.

The decline in equity despite rising retained earnings indicates substantial buyback activity, which enhances per-share metrics but reduces the equity cushion. This strategy appears deliberate, as management prioritizes returning capital over maintaining a large equity base. However, the shrinking equity amplifies the impact of debt on leverage ratios, making the balance sheet appear more strained than historically.

The current ratio below 1.0 suggests that current liabilities exceed current assets, a notable shift from the prior comfortable liquidity position. This deterioration appears driven by increased debt and reduced cash, likely due to buybacks. While the company generates strong operating cash flow, the thin liquidity buffer may limit flexibility in case of an operational shock or unexpected capital need.